Beijing Beilu Pharmaceutical (300016) — Strategic Asset Allocation Index
Beijing Beilu Pharmaceutical (300016) has a Strategic Asset Allocation Index of 45.1% as of June 2023. Strategic assets (PP&E of CN¥853.80 Million plus long-term investments of CN¥-) total CN¥853.80 Million, measured against net assets of CN¥1.89 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check 300016 financial resilience to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Beijing Beilu Pharmaceutical Strategic Asset Allocation Index (2006–2021)
This chart shows how Beijing Beilu Pharmaceutical's Strategic Asset Allocation Index has evolved across 16 annual periods from 2006 to 2021. As of June 2023, the index stands at 45.1%, representing strategic assets of CN¥853.80 Million against net assets of CN¥1.89 Billion CNY. See 300016 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Beijing Beilu Pharmaceutical (2006–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Beijing Beilu Pharmaceutical from 2006 to 2021, covering 16 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market value of Beijing Beilu Pharmaceutical.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 38.1% | CN¥793.92 Million | CN¥793.92 Million | CN¥- | CN¥2.08 Billion | ▼ -1.0 pp |
| 2020 | 39.1% | CN¥739.48 Million | CN¥739.48 Million | CN¥- | CN¥1.89 Billion | ▼ -29.8 pp |
| 2019 | 68.9% | CN¥998.95 Million | CN¥353.26 Million | CN¥645.69 Million | CN¥1.45 Billion | ▲ +3.8 pp |
| 2018 | 65.1% | CN¥784.49 Million | CN¥331.94 Million | CN¥452.54 Million | CN¥1.21 Billion | ▲ +11.1 pp |
| 2017 | 54.0% | CN¥577.23 Million | CN¥283.25 Million | CN¥293.98 Million | CN¥1.07 Billion | ▲ +1.0 pp |
| 2016 | 53.0% | CN¥478.05 Million | CN¥255.87 Million | CN¥222.18 Million | CN¥901.69 Million | ▲ +23.2 pp |
| 2015 | 29.8% | CN¥278.27 Million | CN¥238.54 Million | CN¥39.73 Million | CN¥932.63 Million | ▲ +0.3 pp |
| 2014 | 29.5% | CN¥196.70 Million | CN¥196.70 Million | CN¥- | CN¥666.33 Million | ▲ +0.8 pp |
| 2013 | 28.7% | CN¥160.81 Million | CN¥160.81 Million | CN¥- | CN¥559.38 Million | ▲ +1.6 pp |
| 2012 | 27.2% | CN¥142.33 Million | CN¥142.33 Million | CN¥- | CN¥523.96 Million | ▲ +11.5 pp |
| 2011 | 15.7% | CN¥77.00 Million | CN¥77.00 Million | CN¥- | CN¥491.47 Million | ▲ +2.2 pp |
| 2010 | 13.4% | CN¥62.88 Million | CN¥62.88 Million | CN¥- | CN¥467.62 Million | ▲ +4.8 pp |
| 2009 | 8.6% | CN¥37.45 Million | CN¥37.45 Million | CN¥- | CN¥433.71 Million | ▼ -18.5 pp |
| 2008 | 27.1% | CN¥36.16 Million | CN¥36.16 Million | CN¥- | CN¥133.23 Million | ▼ -15.1 pp |
| 2007 | 42.3% | CN¥38.17 Million | CN¥38.17 Million | CN¥- | CN¥90.33 Million | ▼ -15.0 pp |
| 2006 | 57.3% | CN¥40.99 Million | CN¥40.99 Million | CN¥- | CN¥71.59 Million | — |